Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

251.95
-1.3400-0.53%
Post-market: 251.950.00000.00%19:33 EDT
Volume:329.92K
Turnover:82.87M
Market Cap:16.68B
PE:19.28
High:256.35
Open:256.35
Low:247.03
Close:253.29
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.66
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):13.07
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.96
PE(LYR):-57.03

Loading ...

Ascendis Pharma A/S files Form 3 for SVP and PAO Mads Bodenhoff

Reuters
·
Mar 19

Ascendis Pharma Director Lisa Morrison Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Ascendis Pharma A/S director Lars Holtug files initial beneficial ownership statement

Reuters
·
Mar 19

Ascendis Pharma A/S files Form 3 for EVP and Head of Research and Product Development Kennett Sprogoe

Reuters
·
Mar 19

Ascendis Pharma EVP and President US Market Jay Donovan Wu files initial beneficial ownership statement

Reuters
·
Mar 19

Ascendis Pharma A/S director Jan Moller Mikkelsen files initial beneficial ownership statement

Reuters
·
Mar 19

Ascendis Pharma EVP Flemming Steen Jensen Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Ascendis Pharma EVP and Chief Medical Officer Aimee Shu files initial beneficial ownership statement

Reuters
·
Mar 19

Ascendis Pharma’s TransCon shows efficacy and safety in Turner Syndrome

TIPRANKS
·
Mar 17

Ascendis reports 9.05 cm/year height velocity at week 52 for TransCon hGH in Turner syndrome Phase 2 trial

Reuters
·
Mar 17

Ascendis Pharma Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

Ascendis Pharma assumed with a Buy at Jefferies

TIPRANKS
·
Mar 16

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Stevanato Group (STVN) and BioNTech SE (BNTX)

TIPRANKS
·
Mar 16

Ascendis Pharma A/S Publishes ApproaCH Trial Week 104 Data Presentation

Reuters
·
Mar 16

RBC Lifts Price Target on Ascendis Pharma to $275 From $250, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 03

RBC Capital Sticks to Their Buy Rating for Ascendis Pharma (ASND)

TIPRANKS
·
Mar 03

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)

TIPRANKS
·
Mar 02

Ascendis Wins FDA Approval For Rare Disease Therapy

Benzinga
·
Mar 02

Ascendis Pharma a/S : Raymond James Raises Target Price to $287 From $271

THOMSON REUTERS
·
Mar 02

Wells Fargo Remains a Buy on Ascendis Pharma (ASND)

TIPRANKS
·
Mar 02